ERIS LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of ERIS LIFESCIENCES have increased by 44.02% YoY .
The Earnings Per Share (EPS) of ERIS LIFESCIENCES has increased by 73.17 % YoY. |
||
ERIS LIFESCIENCES Last 5 Annual Financial Results
[BOM: 540596|NSE : ERIS]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹2,894 Cr | ₹2,009 Cr | ₹16,851 Cr | ₹1,347 Cr | ₹1,212 Cr |
| Expenses | ₹1,876 Cr | ₹1,334 Cr | ₹11,484 Cr | ₹862 Cr | ₹781 Cr |
| Operating Profit (Excl OI) | ₹1,017 Cr | ₹675 Cr | ₹5,367 Cr | ₹485 Cr | ₹431 Cr |
| Other Income | ₹18 Cr | ₹24 Cr | ₹112 Cr | ₹26 Cr | ₹8.71 Cr |
| Interest | ₹231 Cr | ₹85 Cr | ₹262 Cr | ₹4.22 Cr | ₹1.98 Cr |
| Depreciation | ₹315 Cr | ₹183 Cr | ₹1,171 Cr | ₹65 Cr | ₹43 Cr |
| Profit Before Tax | ₹489 Cr | ₹431 Cr | ₹4,046 Cr | ₹442 Cr | ₹394 Cr |
| Profit After Tax | ₹375 Cr | ₹397 Cr | ₹3,742 Cr | ₹406 Cr | ₹355 Cr |
| Consolidated Net Profit | ₹352 Cr | ₹392 Cr | ₹3,822 Cr | ₹406 Cr | ₹355 Cr |
| Earnings Per Share (Rs) | ₹44.73 | ₹25.83 | ₹28.83 | ₹28.10 | ₹29.88 |
| PAT Margin (%) | 19.90 | 12.60 | 18.78 | 21.20 | 29.09 |
| ROE(%) | 19.23 | 13.81 | 16.64 | 18.25 | 23.33 |
| ROCE(%) | 14.47 | 13.59 | 12.37 | 17.30 | 25.29 |
| Total Debt/Equity(x) | 0.59 | 0.85 | 1.06 | 0.38 | 0.02 |
Key Financials |
||
| Market Cap | : | ₹ 17,366.6 Cr |
| Revenue (TTM) | : | ₹ 3,329.6 Cr |
| Net Profit(TTM) | : | ₹ 720.8 Cr |
| EPS (TTM) | : | ₹ 52.0 |
| P/E (TTM) | : | 24.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ERIS LIFESCIENCES | 6.3% | 9% | -22.8% |
| SUN PHARMACEUTICAL INDUSTRIES | 8.1% | 9.3% | 9% |
| DIVIS LABORATORIES | 10.5% | 18% | 51.4% |
| TORRENT PHARMACEUTICALS | 2.9% | 2.1% | 30.7% |
| CIPLA | 1.4% | 8.1% | -6.8% |
| DR REDDYS LABORATORIES | -0.1% | 16% | 14.6% |
| MANKIND PHARMA | 4% | 7.5% | 5.8% |
| LUPIN | -0.8% | 2.7% | 0.2% |
| ZYDUS LIFESCIENCES | -3.2% | 7.6% | 21.9% |
ERIS LIFESCIENCES Revenues
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 44.02 % |
| 5 Yr CAGR | 24.31 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,894 Cr | 44.02 | |
| Mar2025 | ₹2,009 Cr | -88.08 | |
| Mar2024 | ₹16,851 Cr | 1,151.00 | |
| Mar2023 | ₹1,347 Cr | 11.15 | |
| Mar2022 | ₹1,212 Cr | - | |
ERIS LIFESCIENCES Operating Profit
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 50.73 % |
| 5 Yr CAGR | 23.96 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,017 Cr | 50.73 | |
| Mar2025 | ₹675 Cr | -87.43 | |
| Mar2024 | ₹5,367 Cr | 1,006.63 | |
| Mar2023 | ₹485 Cr | 12.60 | |
| Mar2022 | ₹431 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 4.64 % |
| 5 Yr CAGR | -0.28 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 35.15% | 4.64 | |
| Mar2025 | 33.59% | 5.46 | |
| Mar2024 | 31.85% | -11.55 | |
| Mar2023 | 36.01% | 1.32 | |
| Mar2022 | 35.54% | - | |
ERIS LIFESCIENCES Profit After Tax
[BOM: 540596|NSE : ERIS]
| Y-o-Y | -10.26 % |
| 5 Yr CAGR | -0.23 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹352 Cr | -10.26 | |
| Mar2025 | ₹392 Cr | -89.74 | |
| Mar2024 | ₹3,822 Cr | 841.01 | |
| Mar2023 | ₹406 Cr | 14.35 | |
| Mar2022 | ₹355 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 57.94 % |
| 5 Yr CAGR | -9.06 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 19.9 % | 57.94 | |
| Mar2025 | 12.6 % | -32.91 | |
| Mar2024 | 18.78 % | -11.42 | |
| Mar2023 | 21.2 % | -27.12 | |
| Mar2022 | 29.09 % | - | |
ERIS LIFESCIENCES Earnings Per Share (EPS)
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 73.17 % |
| 5 Yr CAGR | 10.61 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹45 | 73.17 | |
| Mar2025 | ₹26 | -10.41 | |
| Mar2024 | ₹29 | 2.60 | |
| Mar2023 | ₹28 | -5.96 | |
| Mar2022 | ₹30 | - | |
ERIS LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 6.48 % |
| 5 Yr CAGR | -13.03 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 14.47% | 6.48 | |
| Mar2025 | 13.59% | 9.86 | |
| Mar2024 | 12.37% | -28.50 | |
| Mar2023 | 17.3% | -31.59 | |
| Mar2022 | 25.29% | - | |
ERIS LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹1,252.1 |
| Current MarketCap | : | ₹ 17,366.6 Cr |
| Updated EOD on | : | Nov 08,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ERIS LIFESCIENCES | 6.3% |
9% |
-22.8% |
| SENSEX | 7% |
11.5% |
-3.5% |
ERIS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 500 | 5.8% | 6.6% | -1.1% |
| BSE 1000 | 5.6% | 5.8% | -0.7% |
| BSE HEALTHCARE | 4.4% | 5.6% | 17.9% |
| BSE 400 MIDSMALLCAP INDEX | 4.4% | 0.7% | 0.2% |
| BSE 250 SMALLCAP INDEX | 3.9% | -1.6% | -0% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | 5.6% | 6% | -0.6% |
| NIFTY MICROCAP 250 | 4.1% | -3.6% | 6.2% |
| NIFTY SMALLCAP 500 | 3.7% | -2.3% | NA |
You may also like the below Video Courses
FAQ about ERIS LIFESCIENCES Financials
How the annual revenues of ERIS LIFESCIENCES have changed ?
The Revenues of ERIS LIFESCIENCES have increased by 44.02% YoY .
How the Earnings per Share (EPS) of ERIS LIFESCIENCES have changed?
The Earnings Per Share (EPS) of ERIS LIFESCIENCES has increased by 73.17 % YoY .
Check out Intrinsic Value of Peers of ERIS LIFESCIENCES
Compare Stock Analytics of Peers of ERIS LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
